Kornimate/medical-research-clean huggingface dataset:
hears-slp: providing slp-delivered hearing health care to individuals with cognitive impairment

Conditions: Hearing Loss; Dementia; Cognitive Impairment

Summary: building upon the hears audiologist-community health worker (chw) model, this study intervention will be delivered by a speech-language pathologist (slp). the primary objective of the study is to develop and test an affordable and accessible hearing rehabilitative intervention that will be delivered by a slp to individuals with cognitive impairment.


Eligibility criteria:
inclusion criteria: * age 60 - 100 years old * english-speaking * lives at home * diagnosis of probable alzheimer's disease or other related dementia according to the core clinical criteria outlined in the national institute on aging (nia) and alzheimer's association guidelines * availability of caregiver/study partner to participate in all study-related visits and who provides ≥8 hours of weekly oversight/care * speech frequency pure tone average (0.5- 4 khz) \>25 db in the better-hearing ear; adult onset hearing loss * stable (for 2 weeks or longer) dosing of medication (e.g. antidepressants, antipsychotics) for neuropsychiatric symptoms exclusion criteria: * current self-reported use of hearing aid or amplification device * medical contraindication to use hearing aids ( e.g. draining ears) * inability to participate in the 1-month follow up
clinical study to evaluate the effectiveness and health economics of a novel portable non-pneumatic active compression device (npcd) for lymphedema/phlebolymphedema

Conditions: Phlebolymphedema; Lymphedema; Chronic Venous Insufficiency

Summary: an open-label, multi-center, prospective va study to evaluate the effectiveness and health economics of a novel portable non-pneumatic active compression device (npcd) for lymphedema/phlebolymphedema

an open-label, multi-center, prospective va study to evaluate the effectiveness and health economics of a novel portable non-pneumatic active compression device (npcd) for lymphedema/phlebolymphedema

Eligibility criteria:
inclusion criteria: * males and females ≥ 18 years of age * capable and willing to sign the informed consent and deemed capable of following the study protocol * subjects must have a diagnosis of unilateral or bilateral lower extremity edema or lower extremity lymphedema/phlebolymphedema as a consequence of chronic venous insufficiency * subjects who have medical clearance using diagnostic confirmation through venous duplex to rule out dvt and superficial/deep reflux exclusion criteria: * inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent * individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy * subjects must not have any diagnosed cognitive or physical impairment that would interfere with the use of the device * non-ambulatory individuals * female: bmi \> 34 (5'4", 200 lbs.) * male: bmi \> 34 (5'9", 230 lbs.) * (max circumference at patella 58 cm; max circumference at gluteal fold 75 cm) * diagnosis of lipedema * diagnosis of active or recurrent cancer (\< 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer) * diagnosis of acute infection (in the last four weeks) * diagnosis of active/open wound/ulcer * diagnosis of acute thrombophlebitis (in last 2 months) * diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months * diagnosis of pulmonary edema * diagnosis of congestive heart failure (uncontrolled/uncompensated) * diagnosis of chronic kidney disease with acute renal failure * diagnosis of epilepsy * subjects with poorly controlled asthma * any condition where increased venous and lymphatic return is undesirable * women who are pregnant, planning a pregnancy or nursing at study entry * participation in any clinical trial of an investigational substance or device during the past 30 days
penetration of ceftaroline into cerebrospinal fluid(csf)

Conditions: Meningitis; Ventriculitis

Summary: ceftaroline is a piece of new cephalosporin very active on resistant staphylococci in methicillin (semr: staphylococcus epidermidis resistant in methicillin, smar: staphylococcus aureus resistant in methicillin)and/or in vancomycin ; ceftaroline is also very active on pneumococci resistant in penicillin and/or 3rd generation of cephalosporins. ceftaroline was approved by the european medicines agency for the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. scientific literature describes a good efficiency in septicemy and/or samr endocarditis. besides, a study on animal shows the efficiency of ceftaroline in meningeal infections with gram-negative bacilli. the rationale of this study is based on the antibacterial spectra of ceftaroline that could be used for the antibacterial treatment (curative and prophylactic) of csf shunt associated infections. to validate this hypothesis, it is necessary to evaluate the concentration of ceftaroline in meningeal compartment after treatment.


Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years) * provision of informed consent prior to any study specific procedures * female patients of childbearing potential may be entered if pregnancy testing is negative and the patient agrees to abstain from procreational sexual intercourse or must use double-barrier contraceptive measures for the duration of the study * presence of an indwelling external cerebrospinal fluid (csf) access device (ventriculostomy or lumbar drain) * presence of inflamed meninges as a result of documented or suspected meningitis or ventriculitis. patients with both clinical symptoms (fever, headache, meningismus, and altered mentation) and laboratory parameters (csf leukocytosis, defined as a csf white blood cell count \[wbc\] of \>10 3, elevated csf protein, defined as csf protein of \>1g/l, reduced csf glucose, defined as csf glucose of \ 5 leukocytes/mm3 of csf. exclusion criteria: * patient has documented history of hypersensitivity or allergic reaction (urticaria, angiooedema, anaphylaxis, desquamative rash) to any β-lactam antimicrobial including cephalosporins (contraindication to cephalosporins) * patient is pregnant or lactating and intends to continue breastfeeding * severe renal insufficiency defined as creatinine clearance \< 50 ml/min. * patients with conditions known or suspected to alter pharmacokinetics (i.e., burn or cystic fibrosis patients) * refusal to participate * person not affiliated with the social security
traditional chinese medicine syndrome identification in paediatric neurology

Conditions: Other Diagnoses and Conditions

Summary: traditional chinese medicine (tcm) has a history of more than two millenniums. it has been a common practice in china, taiwan, japan and korea and is becoming increasingly popular worldwide in recent decades however, there is no general consensus for treatment of many diseases among tcm practitioners. in some specialties, such as neurology, there is not enough well documented case reports for practitioners to make reference with. different practitioners may give different opinions according to their own experience and patients often feel frustrated about that. therefore, it is worth recording cases of neurological diseases, with accurate western medicine diagnosis and tcm theory explained. possible tcm treatments can be suggested accordingly. being an academic research supervised by western medicine doctor, this study can help to suggest more objective opinion with least conflict of interest.

traditional chinese medicine (tcm) has a history of more than two millenniums. it has been a common practice in china, taiwan, japan and korea. in recent decades, it is becoming increasingly popular worldwide(victor s. sierpina 2005). studies in hong kong, showed that tcm is quite common among children in hong kong, with about a quarter of children consulting a pediatrician are concurrently using chinese medicine.(lee 2006; li 2006). however, there is a lack of standardized protocol for treatment of many diseases among tcm practitioners. in some specialties, such as neurology, there is not enough well documented case reports for tcm practitioners to make reference. different tcm practitioners may give different opinions according to their own experience and patients often feel frustrated about that. therefore, it is worth recording cases of neurological diseases, with accurate western medicine diagnosis and tcm theory explained. possible tcm treatments can be suggested accordingly. being an academic research supervised by western medicine doctor, this study can help to suggest more objective opinion with least conflict of interest.

Eligibility criteria:
inclusion criteria: * patients receiving medical care in the department of paediatrics and adolescent medicine in queen mary hospital or the duchess of kent children's hospital, and * patients (or their care takers) who are able to provide accurate information about their signs and symptoms exclusion criteria: * patients (or their care takers) who are unable to report a reliable medical history
continuous versus single injection adductor canal blocks for outpatient total knee arthroplasty

Conditions: Acute Postoperative Pain; Surgery

Summary: this is a single-center pilot study to determine if an adductor canal continuous nerve block is superior to single injection nerve block following total knee arthroplasty. investigators will randomize participants to either continuous nerve block or single injection nerve block for the adductor canal preoperatively. they will assess differences in pain (measured in numeric rating scale), opioid consumption, and physical therapy milestones from postoperative day 0 to 7.

adductor canal blocks are standard care for postoperative analgesia following total knee arthroplasty. adductor canal blocks involve depositing local anesthetic (ropivacaine) around the saphenous nerve at the location of the adductor canal on the ipsilateral thigh. at ucsd, the standard care is to perform single injection adductor canal blocks for research participants undergoing total knee arthroplasty prior to surgery in the preoperative waiting area. participants will be randomized to either: (1) single injection with ropivacaine (0.5%) of the adductor canal block and a 5-day continuous perineural infusion of ropivacaine (0.2%) (experimental group); versus (2) single injection with ropivacaine (0.5%) of the adductor canal block and no continuous nerve block added.

Eligibility criteria:
inclusion criteria: 1. adult participants of at least 18 years of age 2. undergoing a primary, unilateral, total knee arthroplasty 3. planned single-injection adductor canal nerve block 4. weight \> 50 kg (to minimize the risk of local anesthetic toxicity) exclusion criteria: 1. chronic opioid or tramadol use: daily oxycodone equivalents \> 20 mg for \> 4 weeks 2. neuro-muscular deficit of the surgical limb 3. moderate pain (nrs \> 3) in an anatomic location other than the surgical site 4. planned hospital admission following surgery 5. history of opioid misuse 6. those who lack capacity to complete informed consent 7. inability to contact the investigators during the treatment period, and vice versa (e.g., lack of telephone access) 8. incarceration 9. pregnancy 10. allergy to amide local anesthetics

Keywords: regional anesthesia total knee arthroplasty nerve block
a study of the effect of dalcetrapib on artherosclerotic disease in patients with coronary artery disease

Conditions: Cardiovascular Disease

Summary: this multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of dalcetrapib in patients with coronary artery disease. atherosclerotic disease progression will be measured 1. coronary intravascular ultrasound (ivus), quantitative coronary angiography 2. carotid b-mode ultrasound intima medial thickness (imt) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease (cad). patients will be randomized to receive dalcetrapib 600 mg orally once a day or placebo. the anticipated time on study treatment will be 24 months. the target sample size is 800-1000 patients.


Eligibility criteria:
inclusion criteria: * adult patients over the age of 18 years * angiographic evidence of coronary artery disease * ultrasound evidence of carotid artery disease * treated appropriately for dyslipidemia exclusion criteria: * previous exposure to any cholesteryl ester transfer protein (cetp) inhibitor or cetp-vaccine within the last 3 months before study start * previous coronary artery bypass graft surgery (cabg) or probable need for cabg in the next 24 months * myocardial infarction in the target coronary artery for ivus between the initial ivus examination and randomization * patients who have symptomatic congestive heart failure at baseline (new york heart association class iii or iv) * severe anemia * uncontrolled hypertension * poorly controlled diabetes
short course radiation therapy in palliative treatment of complicated bone metastases

Conditions: Bone Metastases; Radiotherapy; Palliative Care

Summary: aim of the study is to assess efficacy of a short course radiation treatment in patients with complicated bone metastases

standard treatment for complicated bone metastases (3000 cgy in 10 daily fractions of 300 cgy each) is compared with experimental treatment (4000 cgy in 4 fractions of 500 cgy twice a day) to demonstrate non-inferiority of this scheme.

Eligibility criteria:
inclusion criteria: * complicated bone metastases from any solid tumor * age \>18 years * ecog performance status 0-3 * symptomatic lesion (nrs \>1) * no changes in analgesic treatment at least in the week before radiotherapy exclusion criteria: * pregnancy * previously irradiation of the same region

Keywords: short course radiotherapy complicated bone metastases
asct for relapsed apl after molecular remission

Conditions: Acute Promyelocytic Leukemia; Relapse

Summary: for relapsed acute promyelocytic leukemia after all-trans retinoic acid (atra) and arsenic treatment, remission can be achieved by chemotherapy with atra and/or arsenic and addition of mylotarg. autologous hematopoietic cell transplantation using a polymerase chain reaction (pcr) negative graft is important treatment option to obtain sustainable remission. this study is to test the efficacy and the safety of conditioning regimen with idarubicin and busulfan for relapsed acute promyelocytic leukemia (apl).

once relapsed acute promyelocytic leukemia achieved molecular remission after all-trans retinoic acid (atra) and arsenic treatment, pbsc was mobilized and collected with further confirmation of molecular remission via rt-pcr. patients received autologous hematopoietic cell transplantation.

Eligibility criteria:
inclusion criteria: * men or women between age 18-60 years old * acute promyelocytic leukemia after relapse with confirmed cytogenetics t(15;17) and molecular analysis (pml-raralpha) * mobilized peripheral cd34+ over 2x106/kg with negative pml-rar alpha confirmed by pcr * european cooperative oncology group performance status 0-3 * serum bilirubin \< 1.5x the upper limit of normal (uln) * serum alanine transaminase (alt)/aspartate transaminase values \< 2.5 x uln * subjects (or their legally acceptable representatives) must signed an informed consent document indicating that they understanding the purpose of and procedures required for the study and are willing to participate in the study exclusion criteria: * woman of child bearing potential * serum creatinine \> 400 micromol/l after initial resuscitation patients with previous grade 2-4 peripheral neuropathy * uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug) * uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, uncontrolled angina, clinically significant pericardial disease, or iii-iv heart failure * known allergy to idarubicin

Keywords: pcr negative
exercise genes: genomic association with exercise reinforcement

Conditions: Overweight; Obesity; Physical Activity

Summary: this study tests whether different physical activity patterns are linked an individual's genes.

the investigators propose that an individual's genetics are one factor that may be associated with the motivating aspect or attractiveness of exercise and therefore the choice to exercise rather than be sedentary. they propose to study the association of the genomic signatures with the reinforcing (motivating) value of different types of exercise. this has never been investigated and may uncover underlying mechanisms that would help to understand individual differences in exercise motivation. the ultimate impact of this work is a greater number of americans being physically active, meeting the united states department of agriculture (usda) dietary guidelines for physical activity, and maintaining a healthy body weight. this study will be funded and undertaken at the grand forks human nutrition research center (gfhnrc). the purpose will be to assess genetic underpinnings of the motivating value of resistance and aerobic exercise, and to determine whether the motivating value of aerobic and resistance exercise are associated with usual participation in these modes of exercise.

Eligibility criteria:
inclusion criteria: * bmi within 18.5-35.0 kg/m2 * healthy enough to exercise * active or inactive (not exercising at this time) exclusion criteria: * taking any drugs that affect energy expenditure (e.g., thyroid, glucose-lowering drugs) * have gained or lost more than 5% of body weight over the past 6 months * use tobacco * pregnant or lactating or plan to become pregnant in the next 6 months * have any health conditions that prevent the individual from safely exercising (e.g., cardiovascular, liver, endocrine, or pulmonary diseases)

Keywords: active not active normal body weight
the effect of progressive muscle relaxation and laughter therapy on women undergoing in vitro fertilization

Conditions: Infertility, Female

Summary: purpose: this study was aimed to evaluate the effect of progressive muscle relaxation exercises and laughter therapy on the mental health and treatment outcomes of women receiving ivf treatment. design: randomized controlled trial with two parallel groups methods: participants were randomly assigned to the intervention (ig; n = 71) and control group (cg; n = 70). the progressive muscle relaxation and laughter therapy was administered to women in the intervention group in the ivf center for 3-4 times and 40 minutes. the cg received routine care. data were collected using baseline and oocyte retrieval day stai and bdi.

infertility, one of the important components of reproductive health, affects one in four couples in developing countries.the emergence of assisted reproductive techniques such as in vitro fertilization (ivf) gives infertile couples the opportunity to have both pregnancy and a baby. couples are affected emotionally during ivf treatment and women experience more problems than men. the majority of women experience emotional problems such as anxiety and depression because of infertility, invasive treatment procedures, physiological effects of gonadotropin stimulation and positive outcome expectation.considering the effect of anxiety and depression on infertile women, it is important to examine the effectiveness of progressive muscle relaxation exercises and laughter therapy as complementary therapy in psychosocial care.

Eligibility criteria:
inclusion criteria: * women between the ages of 20 and 46, * literate in turkish language, * diagnosed with infertility by an obstetrician or medical doctor * those with primary or secondary infertility exclusion criteria: * a diagnosed psychiatric disorder, * prior experience in relaxation intervention, * lack of ovarian response in previous treatments * undergoing frozen embryo transfer.
cardiovascular risk and identification of potential high-risk population in acute myocardial infarction

Conditions: Long-term Major Cardiovascular Events; Myocardial Infarction; Percutaneous Coronary Intervention

Summary: the purpose of this registry is to evaluate long-term clinical events in patients with acute myocardial infarction who were treated with percutaneous coronary intervention. although numerous articles have been published by using nationwide korean myocardial infarction registries, such as the korea acute myocardial infarction registry (kamir), limitation of previous registries is that these have little data beyond the first year of mi. therefore, current registry was designed to assess long-term clinical events in patients with acute myocardial infarction. because most of myocardial infarction patients were treated by revascularization in real world of korea, this registry limits the inclusion criteria to patients who were treated with percutaneous coronary intervention to reduce the bias.

cardiovascular center with high-volume percutaneous coronary intervention of following hospitals were participated. * seoul st. mary's hospital, seoul, south korea * yeoido st. mary's hospital, seoul, south korea * uijongbu st. mary's hospital, gyeonggi-do, south korea * st. paul hospital, seoul, south korea * bucheon st. mary's hospital, gyeonggi-do, south korea * incheon st. mary's hospital, incheon, south korea * st. vincent hospital, gyeonggi-do, south korea * deajon st. mary's hospital, daejeon, south korea * cheonnam university hospital, gwangju, south korea 8 hospitals of the catholic university of korea already have web-based coronary intervention registry (nct01239914). and cheonnam university hospital is one of leading hospitals to design and manage the web-based previous korean nationwide myocardial infarction registry, such as such as the korea acute myocardial infarction registry (kamir) (http://www.kamir.or.kr/). all consecutive acute myocardial infarction patients had been enrolled in each registries prospectively. using these previous data, current registry update new clinical and angiographic variables and assess long-term clinical follow-up data retrospectively.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction who were treated with percutaneous coronary intervention exclusion criteria: * acute myocardial infarction who were managed by conservative strategy * acute myocardial infarction who were not treated with percutaneous coronary intervention